EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients

Aims: EndoBarrier is a 60cm duodenal–jejunal bypass liner endoscopically implanted for up to one year and designed to mimic the by‐pass part of Roux‐en‐Y bariatric surgery. We aimed to assess the safety and efficacy of EndoBarrier in patients with suboptimally‐controlled diabesity. Methods: Between...

Full description

Saved in:
Bibliographic Details
Published in:Practical diabetes (2011) 2022-05, Vol.39 (3), p.13-16a
Main Authors: Ryder, Robert EJ, Yadagiri, Mahi, Burbridge, Wyn, Irwin, Susan P, Gandhi, Hardeep, Bashir, Tahira, Allden, Rachael A, Wyres, Melanie, Cull, Melissa, Bleasdale, John P, Fogden, Edward N, Anderson, Mark R, Gupta, Piya Sen
Format: Article
Language:English
Subjects:
Abscesses
bariatric surgery
diabesity
Diabetes
DJBL
duodenal–jejunal bypass liner
EndoBarrier
Endoscopy
Gastrointestinal surgery
Insulin
Obesity
Remission (Medicine)
Surgical outcomes
Transplants & implants
type 2 diabetes
Weight control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1383-778469e1db49445dc7c6bdf4705bcb6f1f8e1234ebc2d0f956f049d7b32f7cd63
cites cdi_FETCH-LOGICAL-c1383-778469e1db49445dc7c6bdf4705bcb6f1f8e1234ebc2d0f956f049d7b32f7cd63
container_end_page 16a
container_issue 3
container_start_page 13
container_title Practical diabetes (2011)
container_volume 39
creator Ryder, Robert EJ
Yadagiri, Mahi
Burbridge, Wyn
Irwin, Susan P
Gandhi, Hardeep
Bashir, Tahira
Allden, Rachael A
Wyres, Melanie
Cull, Melissa
Bleasdale, John P
Fogden, Edward N
Anderson, Mark R
Gupta, Piya Sen
description Aims: EndoBarrier is a 60cm duodenal–jejunal bypass liner endoscopically implanted for up to one year and designed to mimic the by‐pass part of Roux‐en‐Y bariatric surgery. We aimed to assess the safety and efficacy of EndoBarrier in patients with suboptimally‐controlled diabesity. Methods: Between July 2013 and November 2017 we implanted 90 EndoBarriers in a single centre with all removed by November 2018. Outcomes were monitored in a registry. Results: All 90 patients have completed one‐year post EndoBarrier removal and, of these, 71/90 (79%) – age 51.3 ± 8.6 years, 46% male, 52% White ethnicity, diabetes duration 13.0 (7.0–17.0) years, 59% insulin‐treated, BMI 41.1 ± 6.5kg/m2) – attended follow‐up and 19/90 (21%) did not attend follow‐up. During EndoBarrier implantation, mean ± SD HbA1c fell by 19.5 ± 18.4mmol/mol from 78.1 ± 18.9 to 58.6 ± 13.6mmol/mol (p 
doi_str_mv 10.1002/pdi.2393
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2673311174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2673311174</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1383-778469e1db49445dc7c6bdf4705bcb6f1f8e1234ebc2d0f956f049d7b32f7cd63</originalsourceid><addsrcrecordid>eNp1kM1KAzEUhQdRsNSCjxBw42Zq_jrpuNNatVDQha6HTHJTUtpkTFJl3sGHNrUKbrybczl8nAOnKM4JHhOM6VWn7Ziymh0VA4q5KGmN8fHvP63FaTGKcY3zVRNOKB4Un3On_a0MwUJAKYBMW3AJGR_QxrtVTNJp61Yo9R0girSVLSSIKNvItxBt6q-R3yXlt9n1DlAPMiBpUs77m20dqjFS3kVQu2TfYdMf-kCjTiabW-NZcWLkJsLoR4fF6_38ZfZYLp8eFrObZakIm7JSiCmvaiC65TXnE62EqlptuMCTVrWVIWYKhDIOraIam3pSGcxrLVpGjVC6YsPi4pDbBf-2g5iatd8FlysbWgnGCCGCZ-ryQKngYwxgmi7YrQx9Q3Czn7vJczf7uTNaHtAPu4H-X655vlt881-TpYLq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2673311174</pqid></control><display><type>article</type><title>EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><source>Alma/SFX Local Collection</source><creator>Ryder, Robert EJ ; Yadagiri, Mahi ; Burbridge, Wyn ; Irwin, Susan P ; Gandhi, Hardeep ; Bashir, Tahira ; Allden, Rachael A ; Wyres, Melanie ; Cull, Melissa ; Bleasdale, John P ; Fogden, Edward N ; Anderson, Mark R ; Gupta, Piya Sen</creator><creatorcontrib>Ryder, Robert EJ ; Yadagiri, Mahi ; Burbridge, Wyn ; Irwin, Susan P ; Gandhi, Hardeep ; Bashir, Tahira ; Allden, Rachael A ; Wyres, Melanie ; Cull, Melissa ; Bleasdale, John P ; Fogden, Edward N ; Anderson, Mark R ; Gupta, Piya Sen</creatorcontrib><description><![CDATA[Aims: EndoBarrier is a 60cm duodenal–jejunal bypass liner endoscopically implanted for up to one year and designed to mimic the by‐pass part of Roux‐en‐Y bariatric surgery. We aimed to assess the safety and efficacy of EndoBarrier in patients with suboptimally‐controlled diabesity. Methods: Between July 2013 and November 2017 we implanted 90 EndoBarriers in a single centre with all removed by November 2018. Outcomes were monitored in a registry. Results: All 90 patients have completed one‐year post EndoBarrier removal and, of these, 71/90 (79%) – age 51.3 ± 8.6 years, 46% male, 52% White ethnicity, diabetes duration 13.0 (7.0–17.0) years, 59% insulin‐treated, BMI 41.1 ± 6.5kg/m2) – attended follow‐up and 19/90 (21%) did not attend follow‐up. During EndoBarrier implantation, mean ± SD HbA1c fell by 19.5 ± 18.4mmol/mol from 78.1 ± 18.9 to 58.6 ± 13.6mmol/mol (p < 0.001), weight by 15.9 ± 8.6kg from 118.4 ± 27.0 to 102.4 ± 27.7kg (p < 0.001), systolic BP from 139.0 ± 15.0mmHg to 126.6 ± 17.6mmHg (p < 0.001), cholesterol from 4.8 ± 1.2 to 4.0 ± 1.0mmol/L (p < 0.001), and serum alanine‐aminotransferase (marker of liver fat) from 31.0 ± 16.5 to 19.8 ± 11.5U/L (p < 0.001). Median (IQR) total daily insulin dose reduced from 98 (53–163) to 30 (0–63) units (p < 0.001). Eleven of 42 (26.2%) insulin treated patients discontinued insulin. One year post‐EndoBarrier 32/71 (45%) demonstrated fully‐sustained improvement, 25/71 (35%) partially‐sustained improvement and 14/71 (20%) reverted to baseline. Of those deteriorating, 10/14 (71%) had depression and/or bereavement. Thirteen of 90 (14%) patients required early EndoBarrier removal: five for gastrointestinal haemorrhage, two for liver abscess, one for non‐hepatic intra‐abdominal abscess, and five for gastrointestinal symptoms. All made a full recovery. Conclusion: Our data demonstrate EndoBarrier as highly effective in patients with refractory diabesity, with maintenance of significant improvement one year after removal in 80% of cases. As it requires only an endoscopic procedure, EndoBarrier treatment is relatively simple and non‐invasive and it deserves further investigation. Copyright © 2022 John Wiley & Sons.]]></description><identifier>ISSN: 2047-2897</identifier><identifier>EISSN: 2047-2900</identifier><identifier>DOI: 10.1002/pdi.2393</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Abscesses ; bariatric surgery ; diabesity ; Diabetes ; DJBL ; duodenal–jejunal bypass liner ; EndoBarrier ; Endoscopy ; Gastrointestinal surgery ; Insulin ; Obesity ; Remission (Medicine) ; Surgical outcomes ; Transplants &amp; implants ; type 2 diabetes ; Weight control</subject><ispartof>Practical diabetes (2011), 2022-05, Vol.39 (3), p.13-16a</ispartof><rights>Copyright © 2022 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1383-778469e1db49445dc7c6bdf4705bcb6f1f8e1234ebc2d0f956f049d7b32f7cd63</citedby><cites>FETCH-LOGICAL-c1383-778469e1db49445dc7c6bdf4705bcb6f1f8e1234ebc2d0f956f049d7b32f7cd63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Ryder, Robert EJ</creatorcontrib><creatorcontrib>Yadagiri, Mahi</creatorcontrib><creatorcontrib>Burbridge, Wyn</creatorcontrib><creatorcontrib>Irwin, Susan P</creatorcontrib><creatorcontrib>Gandhi, Hardeep</creatorcontrib><creatorcontrib>Bashir, Tahira</creatorcontrib><creatorcontrib>Allden, Rachael A</creatorcontrib><creatorcontrib>Wyres, Melanie</creatorcontrib><creatorcontrib>Cull, Melissa</creatorcontrib><creatorcontrib>Bleasdale, John P</creatorcontrib><creatorcontrib>Fogden, Edward N</creatorcontrib><creatorcontrib>Anderson, Mark R</creatorcontrib><creatorcontrib>Gupta, Piya Sen</creatorcontrib><title>EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients</title><title>Practical diabetes (2011)</title><description><![CDATA[Aims: EndoBarrier is a 60cm duodenal–jejunal bypass liner endoscopically implanted for up to one year and designed to mimic the by‐pass part of Roux‐en‐Y bariatric surgery. We aimed to assess the safety and efficacy of EndoBarrier in patients with suboptimally‐controlled diabesity. Methods: Between July 2013 and November 2017 we implanted 90 EndoBarriers in a single centre with all removed by November 2018. Outcomes were monitored in a registry. Results: All 90 patients have completed one‐year post EndoBarrier removal and, of these, 71/90 (79%) – age 51.3 ± 8.6 years, 46% male, 52% White ethnicity, diabetes duration 13.0 (7.0–17.0) years, 59% insulin‐treated, BMI 41.1 ± 6.5kg/m2) – attended follow‐up and 19/90 (21%) did not attend follow‐up. During EndoBarrier implantation, mean ± SD HbA1c fell by 19.5 ± 18.4mmol/mol from 78.1 ± 18.9 to 58.6 ± 13.6mmol/mol (p < 0.001), weight by 15.9 ± 8.6kg from 118.4 ± 27.0 to 102.4 ± 27.7kg (p < 0.001), systolic BP from 139.0 ± 15.0mmHg to 126.6 ± 17.6mmHg (p < 0.001), cholesterol from 4.8 ± 1.2 to 4.0 ± 1.0mmol/L (p < 0.001), and serum alanine‐aminotransferase (marker of liver fat) from 31.0 ± 16.5 to 19.8 ± 11.5U/L (p < 0.001). Median (IQR) total daily insulin dose reduced from 98 (53–163) to 30 (0–63) units (p < 0.001). Eleven of 42 (26.2%) insulin treated patients discontinued insulin. One year post‐EndoBarrier 32/71 (45%) demonstrated fully‐sustained improvement, 25/71 (35%) partially‐sustained improvement and 14/71 (20%) reverted to baseline. Of those deteriorating, 10/14 (71%) had depression and/or bereavement. Thirteen of 90 (14%) patients required early EndoBarrier removal: five for gastrointestinal haemorrhage, two for liver abscess, one for non‐hepatic intra‐abdominal abscess, and five for gastrointestinal symptoms. All made a full recovery. Conclusion: Our data demonstrate EndoBarrier as highly effective in patients with refractory diabesity, with maintenance of significant improvement one year after removal in 80% of cases. As it requires only an endoscopic procedure, EndoBarrier treatment is relatively simple and non‐invasive and it deserves further investigation. Copyright © 2022 John Wiley & Sons.]]></description><subject>Abscesses</subject><subject>bariatric surgery</subject><subject>diabesity</subject><subject>Diabetes</subject><subject>DJBL</subject><subject>duodenal–jejunal bypass liner</subject><subject>EndoBarrier</subject><subject>Endoscopy</subject><subject>Gastrointestinal surgery</subject><subject>Insulin</subject><subject>Obesity</subject><subject>Remission (Medicine)</subject><subject>Surgical outcomes</subject><subject>Transplants &amp; implants</subject><subject>type 2 diabetes</subject><subject>Weight control</subject><issn>2047-2897</issn><issn>2047-2900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kM1KAzEUhQdRsNSCjxBw42Zq_jrpuNNatVDQha6HTHJTUtpkTFJl3sGHNrUKbrybczl8nAOnKM4JHhOM6VWn7Ziymh0VA4q5KGmN8fHvP63FaTGKcY3zVRNOKB4Un3On_a0MwUJAKYBMW3AJGR_QxrtVTNJp61Yo9R0girSVLSSIKNvItxBt6q-R3yXlt9n1DlAPMiBpUs77m20dqjFS3kVQu2TfYdMf-kCjTiabW-NZcWLkJsLoR4fF6_38ZfZYLp8eFrObZakIm7JSiCmvaiC65TXnE62EqlptuMCTVrWVIWYKhDIOraIam3pSGcxrLVpGjVC6YsPi4pDbBf-2g5iatd8FlysbWgnGCCGCZ-ryQKngYwxgmi7YrQx9Q3Czn7vJczf7uTNaHtAPu4H-X655vlt881-TpYLq</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Ryder, Robert EJ</creator><creator>Yadagiri, Mahi</creator><creator>Burbridge, Wyn</creator><creator>Irwin, Susan P</creator><creator>Gandhi, Hardeep</creator><creator>Bashir, Tahira</creator><creator>Allden, Rachael A</creator><creator>Wyres, Melanie</creator><creator>Cull, Melissa</creator><creator>Bleasdale, John P</creator><creator>Fogden, Edward N</creator><creator>Anderson, Mark R</creator><creator>Gupta, Piya Sen</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>202205</creationdate><title>EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients</title><author>Ryder, Robert EJ ; Yadagiri, Mahi ; Burbridge, Wyn ; Irwin, Susan P ; Gandhi, Hardeep ; Bashir, Tahira ; Allden, Rachael A ; Wyres, Melanie ; Cull, Melissa ; Bleasdale, John P ; Fogden, Edward N ; Anderson, Mark R ; Gupta, Piya Sen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1383-778469e1db49445dc7c6bdf4705bcb6f1f8e1234ebc2d0f956f049d7b32f7cd63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Abscesses</topic><topic>bariatric surgery</topic><topic>diabesity</topic><topic>Diabetes</topic><topic>DJBL</topic><topic>duodenal–jejunal bypass liner</topic><topic>EndoBarrier</topic><topic>Endoscopy</topic><topic>Gastrointestinal surgery</topic><topic>Insulin</topic><topic>Obesity</topic><topic>Remission (Medicine)</topic><topic>Surgical outcomes</topic><topic>Transplants &amp; implants</topic><topic>type 2 diabetes</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ryder, Robert EJ</creatorcontrib><creatorcontrib>Yadagiri, Mahi</creatorcontrib><creatorcontrib>Burbridge, Wyn</creatorcontrib><creatorcontrib>Irwin, Susan P</creatorcontrib><creatorcontrib>Gandhi, Hardeep</creatorcontrib><creatorcontrib>Bashir, Tahira</creatorcontrib><creatorcontrib>Allden, Rachael A</creatorcontrib><creatorcontrib>Wyres, Melanie</creatorcontrib><creatorcontrib>Cull, Melissa</creatorcontrib><creatorcontrib>Bleasdale, John P</creatorcontrib><creatorcontrib>Fogden, Edward N</creatorcontrib><creatorcontrib>Anderson, Mark R</creatorcontrib><creatorcontrib>Gupta, Piya Sen</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Practical diabetes (2011)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ryder, Robert EJ</au><au>Yadagiri, Mahi</au><au>Burbridge, Wyn</au><au>Irwin, Susan P</au><au>Gandhi, Hardeep</au><au>Bashir, Tahira</au><au>Allden, Rachael A</au><au>Wyres, Melanie</au><au>Cull, Melissa</au><au>Bleasdale, John P</au><au>Fogden, Edward N</au><au>Anderson, Mark R</au><au>Gupta, Piya Sen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients</atitle><jtitle>Practical diabetes (2011)</jtitle><date>2022-05</date><risdate>2022</risdate><volume>39</volume><issue>3</issue><spage>13</spage><epage>16a</epage><pages>13-16a</pages><issn>2047-2897</issn><eissn>2047-2900</eissn><abstract><![CDATA[Aims: EndoBarrier is a 60cm duodenal–jejunal bypass liner endoscopically implanted for up to one year and designed to mimic the by‐pass part of Roux‐en‐Y bariatric surgery. We aimed to assess the safety and efficacy of EndoBarrier in patients with suboptimally‐controlled diabesity. Methods: Between July 2013 and November 2017 we implanted 90 EndoBarriers in a single centre with all removed by November 2018. Outcomes were monitored in a registry. Results: All 90 patients have completed one‐year post EndoBarrier removal and, of these, 71/90 (79%) – age 51.3 ± 8.6 years, 46% male, 52% White ethnicity, diabetes duration 13.0 (7.0–17.0) years, 59% insulin‐treated, BMI 41.1 ± 6.5kg/m2) – attended follow‐up and 19/90 (21%) did not attend follow‐up. During EndoBarrier implantation, mean ± SD HbA1c fell by 19.5 ± 18.4mmol/mol from 78.1 ± 18.9 to 58.6 ± 13.6mmol/mol (p < 0.001), weight by 15.9 ± 8.6kg from 118.4 ± 27.0 to 102.4 ± 27.7kg (p < 0.001), systolic BP from 139.0 ± 15.0mmHg to 126.6 ± 17.6mmHg (p < 0.001), cholesterol from 4.8 ± 1.2 to 4.0 ± 1.0mmol/L (p < 0.001), and serum alanine‐aminotransferase (marker of liver fat) from 31.0 ± 16.5 to 19.8 ± 11.5U/L (p < 0.001). Median (IQR) total daily insulin dose reduced from 98 (53–163) to 30 (0–63) units (p < 0.001). Eleven of 42 (26.2%) insulin treated patients discontinued insulin. One year post‐EndoBarrier 32/71 (45%) demonstrated fully‐sustained improvement, 25/71 (35%) partially‐sustained improvement and 14/71 (20%) reverted to baseline. Of those deteriorating, 10/14 (71%) had depression and/or bereavement. Thirteen of 90 (14%) patients required early EndoBarrier removal: five for gastrointestinal haemorrhage, two for liver abscess, one for non‐hepatic intra‐abdominal abscess, and five for gastrointestinal symptoms. All made a full recovery. Conclusion: Our data demonstrate EndoBarrier as highly effective in patients with refractory diabesity, with maintenance of significant improvement one year after removal in 80% of cases. As it requires only an endoscopic procedure, EndoBarrier treatment is relatively simple and non‐invasive and it deserves further investigation. Copyright © 2022 John Wiley & Sons.]]></abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><doi>10.1002/pdi.2393</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2047-2897
ispartof Practical diabetes (2011), 2022-05, Vol.39 (3), p.13-16a
issn 2047-2897
2047-2900
language eng
recordid cdi_proquest_journals_2673311174
source Wiley-Blackwell Read & Publish Collection; Alma/SFX Local Collection
subjects Abscesses
bariatric surgery
diabesity
Diabetes
DJBL
duodenal–jejunal bypass liner
EndoBarrier
Endoscopy
Gastrointestinal surgery
Insulin
Obesity
Remission (Medicine)
Surgical outcomes
Transplants & implants
type 2 diabetes
Weight control
title EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T09%3A31%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EndoBarrier%20treatment%20for%20longstanding%20type%202%20diabetes%20and%20obesity:%20outcomes%20one%20year%20after%20EndoBarrier%20in%2090%20consecutively%20treated%20patients&rft.jtitle=Practical%20diabetes%20(2011)&rft.au=Ryder,%20Robert%20EJ&rft.date=2022-05&rft.volume=39&rft.issue=3&rft.spage=13&rft.epage=16a&rft.pages=13-16a&rft.issn=2047-2897&rft.eissn=2047-2900&rft_id=info:doi/10.1002/pdi.2393&rft_dat=%3Cproquest_cross%3E2673311174%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1383-778469e1db49445dc7c6bdf4705bcb6f1f8e1234ebc2d0f956f049d7b32f7cd63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2673311174&rft_id=info:pmid/&rfr_iscdi=true